All bisphosphonates are (or may not be) the same: potential reasons for clinical differences.

[1]  P. Miller.  Fragility fractures in chronic kidney disease: An opinion-based approach , 2009, Cleveland Clinic Journal of Medicine.

[2]  P. Miller,et al.  Perspective: Assessing the Clinical Utility of Serum CTX in Postmenopausal Osteoporosis and Its Use in Predicting Risk of Osteonecrosis of the Jaw , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[3]  R. Recker,et al.  Targeting Bone Remodeling for the Treatment of Osteoporosis: Summary of the Proceedings of an ASBMR Workshop , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[4]  S. Boonen,et al.  Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. , 2008, Kidney international.

[5]  J. Reginster,et al.  Role of biochemical markers of bone turnover as prognostic indicator of successful osteoporosis therapy. , 2008, Bone.

[6]  P. Miller.  Non-vertebral fracture risk reduction with oral bisphosphonates: challenges with interpreting clinical trial data , 2008, Current medical research and opinion.

[7]  J. Reginster,et al.  Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study , 2008, Current medical research and opinion.

[8]  P. Miller,et al.  Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies* , 2008, Current medical research and opinion.

[9]  S. Cremers,et al.  Bone markers--new aspects. , 2008, Clinical laboratory.

[10]  N. Watts,et al.  Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy , 2008, Osteoporosis International.

[11]  S. Boonen,et al.  Zoledronic acid and clinical fractures and mortality after hip fracture. , 2007, The New England journal of medicine.

[12]  P. Miller,et al.  Renal safety of intravenous bisphosphonates in the treatment of osteoporosis , 2007, Expert opinion on drug safety.

[13]  E. Seeman.  Is a change in bone mineral density a sensitive and specific surrogate of anti-fracture efficacy? , 2007, Bone.

[14]  S. Cummings,et al.  Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. , 2007, The New England journal of medicine.

[15]  P. Miller.  Monitoring osteoporosis therapies , 2007, Current osteoporosis reports.

[16]  F. Bauss,et al.  Effects of ibandronate on bone quality: preclinical studies. , 2007, Bone.

[17]  S M Jorgensen,et al.  Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography. , 2006, Bone.

[18]  D. Kiel,et al.  Comparison of Weekly Treatment of Postmenopausal Osteoporosis with Alendronate Versus Risedronate Over Two Years , 2006 .

[19]  G. H. Nancollas,et al.  Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. , 2006, Bone.

[20]  L. Shulman,et al.  Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both? , 2006, The American journal of medicine.

[21]  P. Geusens,et al.  Relationship Between Changes in BMD and Nonvertebral Fracture Incidence Associated With Risedronate: Reduction in Risk of Nonvertebral Fracture Is Not Related to Change in BMD , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[22]  S. Boonen,et al.  Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies , 2005, Osteoporosis International.

[23]  M. Hochberg,et al.  How useful are measures of BMD and bone turnover?* , 2005, Current medical research and opinion.

[24]  D. Williams,et al.  The influence of pyrophosphate, condensed phosphates, phosphonates and other phosphate compounds on the dissolution of hydroxyapatitein vitro and on bone resorption induced by parathyroid hormone in tissue culture and in thyroparathyroidectomised rats , 2005, Calcified Tissue Research.

[25]  C. Christiansen,et al.  Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[26]  M. Rogers.  New insights into the molecular mechanisms of action of bisphosphonates. , 2003, Current pharmaceutical design.

[27]  C. Christiansen,et al.  Biochemical markers for prediction of 4-year response in bone mass during bisphosphonate treatment for prevention of postmenopausal osteoporosis. , 2003, Bone.

[28]  R. Eastell,et al.  Relationship of Early Changes in Bone Resorption to the Reduction in Fracture Risk With Risedronate , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[29]  T. Dufresne,et al.  Risedronate Preserves Trabecular Architecture and Increases Bone Strength in Vertebra of Ovariectomized Minipigs as Measured by Three‐Dimensional Microcomputed Tomography , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[30]  P Geusens,et al.  Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. , 2001, The New England journal of medicine.

[31]  M. Rogers,et al.  Bisphosphonates: from the laboratory to the clinic and back again. , 1999, Bone.

[32]  S. Cummings,et al.  Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures , 1996, The Lancet.